Keyword: Infinity Pharmaceuticals
Arcus Biosciences and Infinity Pharmaceuticals plan to mix their lead programs in triple-combination immunotherapy trials in breast and ovarian cancer.
Verastem says it is eyeing early 2018 for a new drug application to the FDA for its new but troubled oncology asset duvelisib.
Wednesday's shot of your news of note.
J&J's vet Ross has left for Henry Shein, House E&C Committee staff director Andres takes public affairs job at BIO, and Infinity's Kutok has been promoted to CSO.
Bristol-Myers Squibb has teamed with Infinity Pharmaceuticals to add another study to its burgeoning roster of combination trials featuring PD-1 drug Opdivo.
In a move that will surprise no one after this month’s poor study, AbbVie has handed back the rights to Infinity’s lead blood cancer candidate duvelisib, while also cutting all ties with the biotech.
Three years after it was forced to restructure the company in the wake of the failure of its then lead drug, Infinity Pharmaceuticals ($INFI) finds itself in a new crisis.